Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Stem Cell Advance May Enhance the Process of Tissue Regeneration

By BiotechDaily International staff writers
Posted on 12 Aug 2014
Image: Induced pluripotent stem cells—known as iPS cells, and which act very much like embryonic stem cells—are here growing into heart cells (blue) and nerve cells (green) (Photo courtesy of the Gladstone Institutes/Chris Goodfellow).
Image: Induced pluripotent stem cells—known as iPS cells, and which act very much like embryonic stem cells—are here growing into heart cells (blue) and nerve cells (green) (Photo courtesy of the Gladstone Institutes/Chris Goodfellow).
A new stem-cell discovery might one day lead to a more streamlined way to obtain stem cells, which then could be used in the development of replacement tissue for declining body parts.

The research builds on a strategy exploited by scientists from the University of California, San Francisco (UCSF; USA) that involves reprogramming adult cells back to an embryonic state in which they again have the potential to become any type of cell. They reported their findings July 17, 2014, issue of the journal Cell.

The efficiency of this process may soon increase due to the scientists’ identification of biochemical pathways that can suppress the necessary reprogramming of gene activity in adult human cells. Taking away these hurdles was shown to increase the efficiency of stem-cell production.

“Our new work has important implications for both regenerative medicine and cancer research,” said Miguel Ramalho-Santos, PhD, an associate professor of obstetrics, gynecology and reproductive sciences and a member of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF, who led the research, funded in part by a NIH Director’s New Innovator Award.

The earlier discovery that it was possible to take specialized adult cells and reverse the developmental clock to strip the mature cells of their distinguishing identities and characteristics, and to make them immortal, reprogrammable cells that theoretically can be used to substitute for any tissue type, led to a share of the Nobel Prize in Physiology or Medicine being awarded to UCSF, Gladstone Institutes and Kyoto University (Japan) researcher Shinya Yamanaka, MD, in 2012.

These induced pluripotent stem (iPS) cells are regarded as an alternative research strategy to ongoing efforts to develop tissue from stem cells obtained from early-stage human embryos. However, in spite of the potential of iPS cells and the enthusiasm surrounding iPS research, the percentage of adult cells effectively transformed to iPS cells is typically low, and the resulting cells often retain indications of their earlier lives as specialized cells.

Researchers generate stem cells by forcing the activation within adult cells of pluripotency-inducing genes, beginning with the so-called “Yamanaka factors,” a process that turns back the clock on cellular maturation. However, as Dr. Ramalho-Santos noted, “from the time of the discovery of iPS cells, it was appreciated that the specialized cells from which they are derived are not a blank slate. They express their own genes that may resist or counter reprogramming.”

But as to what precisely was getting in the way of reprogramming remained little understood. “Now, by genetically removing multiple barriers to reprogramming, we have found that the efficiency of generation of iPS cells can be greatly increased,” Dr. Ramalho-Santos said. The discovery, he reported, will contribute to accelerating the safe and effective use of iPS cells and other reprogrammed cells.

The researchers found not only isolated genes acting as barriers, but rather sets of genes acting together through different mechanisms to create roadblocks to reprogramming. “At practically every level of a cell’s functions there are genes that act in an intricately coordinated fashion to antagonize reprogramming,” Dr. Ramalho-Santos said.

These processes are likely to help adult cells maintain their characteristics and functional roles. “Much like the Red Queen running constantly to remain in the same place in Lewis Carroll’s ‘Through the Looking-Glass,’ adult cells appear to put a lot of effort into remaining in the same state,” he said.

To uncover this earlier unidentified busy biochemical environment of inhibitory gene activity, the scientists had to simultaneously master a few different technical coups in the lab. They combined advanced cellular, genetic, and bioinformatics technologies to comprehensively identify genes that act as barriers to the generation of human iPS cells, and examined how these distinctive barriers work.

Apart from maintaining the stability of adult tissues, the barrier genes most likely serve important roles in other diseases—including in the prevention of various cancers, according to Dr. Ramalho-Santos.


Related Links:
University of California, San Francisco


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: To adhere to catheters and start urinary tract infections, bacteria extend microscopic fibers with sticky proteins at their ends. Researchers have developed a vaccine that blocks the EbpA protein, visible as a white bulge above, and stops infections in mice (Photo courtesy of Dr. John Heuser, Washington University School of Medicine).

Blocking Binding of Bacteria to Fibrinogen Prevents Biofilm Formation and Catheter-Associated Bladder Infection in Mice

A team of molecular microbiologists has identified and targeted a critical step in biofilm formation and developed a vaccine that prevents catheter-associated urinary tract infections in mice.... Read more

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.